KB-1332

Farletuzumab

Home » Antibody » Farletuzumab

Background

Farletuzumab, also known as MORAb-003 , constitutes a humanized monoclonal antibody with an affinity for the folate receptor a. In laboratory settings, farletuzumab exhibits the capacity to impede folate receptor a-dependent cell proliferation while instigating tumor cell destruction through complement-dependent cytotoxicity and antibody-dependent cytotoxicity mechanisms. Further bolstering its therapeutic potential, evidence suggests that farletuzumab restrains tumor growth by hindering lyn kinase phosphorylation mediated by folate receptor a. Notably, comprehensive immunohistochemical analyses conducted on human and primate tissues affirm the specificity of farletuzumab's binding to its target, displaying an absence of cross-reactivity with normal tissues.

Specifications

Catalog Number:
KB-1332
Cell Line Name:
Farletuzumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
FOLR1
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. Ebel?W, Routhier?EL, Foley?B, et al.?Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-¦Á. Cancer Immun?2007;7:6. 2. Kelemen?LE.?The role of folate receptor ¦Á in cancer development, progression and treatment: cause, consequence or innocent bystander??Int J Cancer?2006;119:243¨C50.
Please enable JavaScript in your browser to complete this form.